Chief Business Officer at evitria
evitria Europe
London, Great Britain
Mail: ds@evitria.com
As Chief Business Officer, Desmond Schofield leads strategic initiatives focused on fostering growth and innovation. His responsibilities include crafting and implementing strategies to enhance customer service and satisfaction within a constantly evolving market.
With a Doctorate in biochemical engineering from the University College London, Desmond Schofield has gained invaluable experience in numerous fields across the biotechnology sector and beyond: he is a professional in business development and new technology ventures; furthermore, Desmond Schofield is experienced in synthetic biology as well as in bioprocessing and immuno-oncology. This and more sums up to a broad portfolio of profound expert knowledge that Desmond Schofield brings to evitria.
LinkedIn profile: Desmond Schofield
Articles
From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.
In the dynamic landscape of antibody research and therapeutics, having a diverse array of purification methods is essential. At Evitria AG, we recognize the need for flexibility to meet various project requirements. Let’s delve into our updated purification services.
Therapeutic antibodies are the fastest-growing class of biological drugs. Their ability to interact with specific targets means they can be employed for a range of diseases, including cancer, autoimmune and infectious diseases.